Exane Derivatives’s Bath & Body Works BBWI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-52
Closed -$3.63K 1022
2021
Q4
$3.63K Hold
52
﹤0.01% 629
2021
Q3
$3.28K Sell
52
-1,613
-97% -$103K ﹤0.01% 764
2021
Q2
$99.8K Buy
+1,665
New +$90K 0.02% 536
2020
Q4
Sell
-1,188
Closed -$30.5K 832
2020
Q3
$30.5K Hold
1,188
0.01% 400
2020
Q2
$14.4K Sell
1,188
-180
-13% -$2.01K ﹤0.01% 404
2020
Q1
$12.8K Hold
1,368
﹤0.01% 419
2019
Q4
$21.9K Sell
1,368
-252,095
-99% -$3.64M ﹤0.01% 388
2019
Q3
$4.01M Buy
253,463
+76,644
+43% +$1.35M 0.72% 24
2019
Q2
$3.73M Buy
176,819
+4,363
+3% +$86.3K 0.65% 38
2019
Q1
$3.84M Buy
172,456
+17,751
+11% +$390K 0.76% 36
2018
Q4
$3.21M Sell
154,705
-23,413
-13% -$590K 0.58% 49
2018
Q3
$4.36M Buy
178,118
+77,239
+77% +$1.93M 0.82% 24
2018
Q2
$3.01M Buy
100,879
+80,601
+397% +$2.33M 0.5% 36
2018
Q1
$621K Buy
20,278
+19,794
+4,090% +$749K 0.12% 151
2017
Q4
$23.6K Sell
484
-13,531
-97% -$547K ﹤0.01% 379
2017
Q3
$471K Buy
14,015
+10,815
+338% +$363K 0.09% 141
2017
Q2
$139K Sell
3,200
-4,010
-56% -$164K 0.03% 234
2017
Q1
$274K Buy
+7,210
New +$325K 0.06% 173

Other funds holding BBWI

Exane Derivatives's BBWI Position: Q1 2022 in Review

Exane Derivatives sold out of Bath & Body Works (BBWI) in Q1 2022, closing a stake of 52 shares — an estimated $3.63K sold.

Exane Derivatives first reported a position in BBWI in Q1 2017 and held it in 18 quarters. The position peaked at $4.36M in Q3 2018. 501 funds tracked by Wall St. Rank hold BBWI as of Q1 2022.

  • Exane Derivatives reported no remaining Bath & Body Works position as of Q1 2022 after selling out during the quarter.
  • Exane Derivatives sold 52 Bath & Body Works shares in Q1 2022, an estimated $3.63K.
  • Exane Derivatives first reported a position in Bath & Body Works in Q1 2017 and held it in 18 quarters.
  • Exane Derivatives's Bath & Body Works position peaked at $4.36M in Q3 2018.
  • 501 funds tracked by Wall St. Rank held Bath & Body Works as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.